 |
Prospector
Profile
07.1223
|
| |
| Isolagen, Inc. |
NAICS |
541710 |
| 405 Eagleview Boulevard
Exton, PA 19341 |
Description |
Biotechnology |
| (484) 713-6000 |
Employees |
55 |
| http://www.isolagen.com/ |
Revenue |
(mil) |
6.0920 |
| |
Income |
(mil) |
-35.8210 |
| |
Assets |
(mil) |
57.2860 |
| |
Liability |
(mil) |
99.0000 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Isolagen, Inc. reported a net loss of $9,740,860 for the three months ended June 30, 2007, compared to a net loss of $8,131,714 during the same period last year. As a result of its recurring losses, the Company has an accumulated deficit of $147,755,297 and stockholder's deficit of $60,206,778 as of June 30, 2007
|
| |
|
Intellectual Property:
As of December 31, 2006, the Company had 7 issued U.S. patents, 9 pending U.S. patent applications, 26 foreign patents and 28 pending foreign patent applications. The issued patents and patent applications primarily cover the method of using autologous cell fibroblasts for the repair of skin and soft tissue defects and the use of autologous fibroblast cells for tissue regeneration. The Company is in the process of pursuing several other patent applications. In January 2003, the Company acquired two pending U.S. patent applications. In August 2006, the Company acquired Agera Laboratories, which has a number of trade names, trademarks, exclusive proprietary rights to product formulations and specified peptides that are used in the Agera skincare products. [SEC Filing 10-K 03-19-07]
|
| |
|
Description:
The Company develops skin and tissue rejuvenation products for application in certain aesthetic and therapeutic markets.
|
| |
|
Officers:
Nicholas L. Teti (Chair & CEO); Susan Stranahan Ciallella (Pres. & Dir.); Declan Daly (EVP & CFO); Steven C. Trider (SVP); Todd J. Greenspan (VP & Controller); Steven Morrell (Dir.); Henry Y.L. Toh (Dir.); Ralph V. De Martino (Dir.); Marshall G. Webb (Dir.); Terry E. Vandewarker (Dir.)
|
| |
|
Auditor:
BDO Seidman LLP
|
| |
|
Securities:
Common Stock-Symbol ILE; AMEX;
30,870,344 common shares outstanding as of August 1, 2007.
|
| |
| |
| |
| return to main page |
|
|
